An immunotherapy drug has been approved by the US Food and Drug Administration to delay the development of type 1 diabetes. The name of the drug is Tzield (teplizumab-mzwv). It is the first drug to prevent type 1 diabetes. According to experts, teplizumab has ushered in a new era in the field of medicine. Experts say that this drug can treat the disease as well as identify the cause of the disease from the beginning. This medication will help reduce the attack on the body’s insulin-producing cells. According to research, about 8.7 million people worldwide have type 1 diabetes. Including many children.
Insulin is a hormone that helps the body use blood sugar. Most treatments focus on checking blood sugar levels and taking insulin by injection. Rachel Connor, from the charity JDRF UK, said “This is a game-changer. It opens a new era for treating type 1 diabetes.”
What is diabetes?
Once diagnosed with diabetes, you have to carry it for the rest of your life. In this disease, a person’s blood sugar level goes up a lot. Diabetes is mainly of two types – type 1 and type 2. In type 1 diabetes, the body’s immune system attacks the main cells of the pancreas itself. That is, it attacks and destroys the cells that make insulin. As a result, insulin is not produced. And, in type 2 diabetes, the body cannot produce enough insulin. Type 2 diabetes is much more common than type 1.